Johnson & Johnson (NYSE:JNJ) Holdings Lifted by Integral Investment Advisors Inc.

Integral Investment Advisors Inc. grew its position in Johnson & Johnson (NYSE:JNJ) by 1.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 16,822 shares of the company’s stock after purchasing an additional 288 shares during the period. Johnson & Johnson makes up approximately 0.8% of Integral Investment Advisors Inc.’s holdings, making the stock its 25th biggest position. Integral Investment Advisors Inc.’s holdings in Johnson & Johnson were worth $2,433,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. AMF Tjanstepension AB lifted its stake in shares of Johnson & Johnson by 14.2% in the 3rd quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock worth $68,985,000 after acquiring an additional 52,997 shares during the period. Alpha Financial Partners LLC acquired a new stake in shares of Johnson & Johnson in the 3rd quarter worth approximately $209,000. Wealth Group Ltd. acquired a new stake in shares of Johnson & Johnson in the 3rd quarter worth approximately $213,000. Swedbank AB lifted its stake in shares of Johnson & Johnson by 5.3% in the 3rd quarter. Swedbank AB now owns 2,215,108 shares of the company’s stock worth $358,980,000 after acquiring an additional 111,570 shares during the period. Finally, Hamlin Capital Management LLC lifted its stake in Johnson & Johnson by 15.3% during the third quarter. Hamlin Capital Management LLC now owns 982,593 shares of the company’s stock valued at $159,239,000 after purchasing an additional 130,305 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on the stock. Citigroup cut their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Leerink Partners cut their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Finally, Wolfe Research assumed coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 target price for the company. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $170.67.

Johnson & Johnson Stock Up 1.5 %

JNJ stock opened at $166.13 on Wednesday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The company has a market cap of $399.98 billion, a price-to-earnings ratio of 24.98, a PEG ratio of 2.56 and a beta of 0.52. The company has a 50 day moving average of $149.72 and a two-hundred day moving average of $155.92.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter in the prior year, the firm earned $2.29 EPS. The company’s revenue was up 5.3% compared to the same quarter last year. On average, equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 2.99%. Johnson & Johnson’s payout ratio is 74.59%.

Insiders Place Their Bets

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the business’s stock in a transaction dated Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. This represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.